Expert opinion on management of moderate-to-severe atopic dermatitis in Qatar

Autor: Martin Steinhoff, Mehdi Adeli, Hassan Riad, Mohamed Allam, Ahmad Hazem, Ra’ed Alsmadi, Adel Mohamed Kamal, Waad Ibrahim, Maryam Ali Al-Nesf
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Druh dokumentu: article
ISSN: 0954-6634
1471-1753
09546634
DOI: 10.1080/09546634.2023.2251622
Popis: Atopic dermatitis (AD), a chronic-relapsing inflammatory skin disorder, manifests with intense itching and eczematous lesions impairing quality of life. A heterogeneous population, and regional clinical practices for treating AD warrant the development of guidelines in Qatar. Therefore, guidelines for the management of moderate-to-severe AD in Qatar have been developed and discussed. Experts, including dermatologists and immunologists, used the Delphi technique for developing guidelines. Consensus was defined as ≥75% agreement or disagreement. AD is highly prevalent in primary and tertiary dermatology centers. AD-associated foot eczema and psoriasiform eczema are more frequent in Qatar than in Europe or USA. SCORing Atopic Dermatitis Index quantifies disease severity and itch. Dermatology Life Quality Index assesses the quality of life. Atopic Dermatitis Control Tool assesses long-term disease control. Moderate-severe AD benefits from new topicals like Janus-kinase-inhibitors or PDE4-inhibitors combined with phototherapy. Currently approved systemic agents are dupilumab, baricitinib, abrocitinib, and upadacitinib. New anti-IL-13 and anti-IL-31 therapies will soon be available. Patient education, allergy testing, and comorbidity consideration are critical in the management of AD. The expert panel established a comprehensive and pragmatic approach to managing moderate-to-severe AD, thereby assisting clinical decision-making for healthcare professionals in Qatar.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje